^
    Apply
    Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) (NCT02905188)
    Phase 1
    Baylor College of Medicine
    Completed
    Last update posted :
    02/24/2025
    Initiation :
    03/28/2019
    Primary completion :
    11/17/2021
    Completion :
    01/06/2023
    GPC3
    |
    GPC3 positive
    |
    cyclophosphamide • fludarabine IV • GLYCAR T cells • cyclophosphamide intravenous
    CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma (NCT06641453)
    Phase 1/2
    Chinese PLA General Hospital
    Not yet recruiting
    Last update posted :
    10/16/2024
    Initiation :
    11/15/2024
    Primary completion :
    11/15/2027
    Completion :
    11/15/2028
    GPC3
    |
    cyclophosphamide • fludarabine IV
    GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC) (NCT05003895)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/05/2024
    Initiation :
    12/08/2021
    Primary completion :
    12/31/2024
    Completion :
    12/31/2025
    GPC3
    |
    GPC3 expression
    |
    cyclophosphamide • fludarabine IV • cyclophosphamide intravenous
    A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma (ATHENA) (NCT06084884)
    Phase 1/2
    AstraZeneca
    Recruiting
    Last update posted :
    05/21/2024
    Initiation :
    11/27/2023
    Primary completion :
    12/13/2027
    Completion :
    12/13/2027
    GPC3
    |
    GPC3 positive
    |
    cyclophosphamide
    Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (NCT04715191)
    Phase 1
    Baylor College of Medicine
    Not yet recruiting
    Last update posted :
    05/06/2024
    Initiation :
    07/03/2024
    Primary completion :
    08/01/2026
    Completion :
    07/03/2041
    GPC3
    |
    GPC3 positive
    |
    cyclophosphamide • fludarabine IV • GLYCAR T cells • GPC3-CAR and IL15 plus IL21 • cyclophosphamide intravenous
    A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma (NCT05155189)
    Phase 1
    Zhejiang University
    Recruiting
    Last update posted :
    04/04/2024
    Initiation :
    12/09/2021
    Primary completion :
    05/01/2026
    Completion :
    05/01/2041
    GPC3
    |
    GPC3 expression
    |
    Lenvima (lenvatinib) • AZD7003
    Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC (NCT05652920)
    Phase 1/2
    OriCell Therapeutics Co., Ltd.
    Recruiting
    Last update posted :
    04/03/2024
    Initiation :
    12/15/2022
    Primary completion :
    12/01/2026
    Completion :
    12/01/2026
    GPC3
    |
    GPC3 expression
    |
    Ori-C101
    To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307 (NCT05783570)
    Phase 1
    Eutilex
    Recruiting
    Last update posted :
    03/15/2024
    Initiation :
    08/24/2023
    Primary completion :
    06/01/2025
    Completion :
    12/01/2025
    IFNG • IL6 • TNFA • GPC3 • IL2 • IL10 • IL18
    |
    EU307
    BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (DUET-1) (NCT05120271)
    Phase 1/2
    Sotio Biotech Inc.
    Recruiting
    Last update posted :
    01/11/2024
    Initiation :
    05/18/2022
    Primary completion :
    04/01/2026
    Completion :
    12/01/2041
    EGFR • ALK • BRCA • GPC3
    |
    EGFR mutation • ALK translocation • BRCA mutation • GPC3 expression • GPC3 overexpression
    |
    cyclophosphamide • BOXR1030
    A Study of TAK-102 in Adult With Previously-Treated Solid Tumors (NCT04405778)
    Phase 1
    Takeda
    Active, not recruiting
    Last update posted :
    12/27/2023
    Initiation :
    07/10/2020
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    GPC3
    |
    GPC3 expression
    |
    NIB102
    B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma (NCT05070156)
    Phase 1
    Tongji University
    Active, not recruiting
    Last update posted :
    12/15/2023
    Initiation :
    10/29/2021
    Primary completion :
    08/31/2024
    Completion :
    09/30/2024
    GPC3
    |
    GPC3 positive
    |
    B010-A
    Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers (NCT05779917)
    Phase 1
    Second Affiliated Hospital of Guangzhou Medical...
    Recruiting
    Last update posted :
    11/15/2023
    Initiation :
    03/10/2023
    Primary completion :
    03/10/2026
    Completion :
    03/10/2033
    MSLN
    |
    MSLN expression • MSLN positive
    |
    Mesothelin/GPC3/GUCY2C-CAR-T
    Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors (NCT05103631)
    Phase 1
    Baylor College of Medicine
    Recruiting
    Last update posted :
    08/23/2023
    Initiation :
    06/17/2021
    Primary completion :
    01/01/2025
    Completion :
    12/01/2039
    GPC3
    |
    GPC3 positive
    |
    cyclophosphamide • fludarabine IV • AGAR T cells • cyclophosphamide intravenous
    Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma (CT0180-CG1203) (NCT04756648)
    Phase 1
    Zhejiang University
    Recruiting
    Last update posted :
    07/17/2023
    Initiation :
    03/10/2021
    Primary completion :
    06/01/2024
    Completion :
    06/01/2024
    PD-L1 • GPC3
    |
    cyclophosphamide • CT0180
    GPC3-targeting LCAR-H93T Cell in Treatment of Advanced Hepatocellular Carcinoma (NCT05352542)
    Phase 1
    jianming xu
    Recruiting
    Last update posted :
    07/11/2023
    Initiation :
    05/19/2022
    Primary completion :
    07/01/2024
    Completion :
    10/01/2026
    GPC3
    |
    LB2101
    Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (NCT04377932)
    Phase 1
    Baylor College of Medicine
    Recruiting
    Last update posted :
    07/07/2023
    Initiation :
    12/08/2021
    Primary completion :
    02/01/2025
    Completion :
    02/01/2040
    GPC3
    |
    GPC3 positive
    |
    cyclophosphamide • fludarabine IV • AGAR T cells • GLYCAR T cells • cyclophosphamide intravenous
    GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma (NCT05926726)
    Phase N/A
    RenJi Hospital
    Recruiting
    Last update posted :
    06/30/2023
    Initiation :
    01/01/2023
    Primary completion :
    12/31/2025
    Completion :
    12/31/2026
    GPC3
    |
    cyclophosphamide
    Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) (NCT02932956)
    Phase 1
    Baylor College of Medicine
    Active, not recruiting
    Last update posted :
    06/06/2023
    Initiation :
    12/17/2018
    Primary completion :
    09/27/2021
    Completion :
    02/01/2037
    GPC3
    |
    GPC3 positive
    |
    cyclophosphamide • fludarabine IV • GAP T cells • cyclophosphamide intravenous
    GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression (ZZCART-003) (NCT03198546)
    Phase 1
    Second Affiliated Hospital of Guangzhou Medical...
    Recruiting
    Last update posted :
    02/28/2023
    Initiation :
    07/01/2017
    Primary completion :
    08/01/2025
    Completion :
    08/01/2029
    GPC3
    |
    GPC3 expression • GPC3 positive
    |
    TGFβ targeting CAR-T cells
    GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers (NCT03198052)
    Phase 1
    Second Affiliated Hospital of Guangzhou Medical...
    Recruiting
    Last update posted :
    02/14/2023
    Initiation :
    07/01/2017
    Primary completion :
    08/01/2024
    Completion :
    08/01/2026
    EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA
    |
    MSLN expression • EGFR positive • GPC3 expression
    |
    GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells
    4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3 (CISLD-4) (NCT03980288)
    Phase 1
    Zhejiang University
    Completed
    Last update posted :
    01/31/2023
    Initiation :
    07/23/2019
    Primary completion :
    12/30/2020
    Completion :
    12/30/2020
    GPC3
    |
    cyclophosphamide • CT0180
    Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma (NCT05620706)
    Phase N/A
    Shenzhen University General Hospital
    Recruiting
    Last update posted :
    11/22/2022
    Initiation :
    11/01/2022
    Primary completion :
    10/31/2025
    Completion :
    10/31/2028
    GPC3
    |
    GPC3 positive
    Novel GPC3 CAR-T Cell Therapy for Hepatocellular Carcinoma (NCT05344664)
    Phase 1
    Peking University
    Not yet recruiting
    Last update posted :
    04/25/2022
    Initiation :
    04/14/2022
    Primary completion :
    10/14/2024
    Completion :
    02/01/2025
    GPC3
    |
    GPC3 positive
    |
    GPC3-CAR-T cells
    Chimeric Antigen Receptor T Cells Targeting Glypican-3 (NCT03884751)
    Phase 1
    CARsgen Therapeutics Co., Ltd.
    Completed
    Last update posted :
    02/24/2022
    Initiation :
    08/15/2019
    Primary completion :
    05/28/2021
    Completion :
    12/03/2021
    GPC3
    |
    CT0180
    GPC3-CAR-T Cells for the Hepatocellular Carcinoma (NCT04506983)
    Phase 1
    Beijing Tsinghua Chang Gung Hospital
    Suspended
    Last update posted :
    02/14/2022
    Initiation :
    06/10/2022
    Primary completion :
    06/10/2023
    Completion :
    10/10/2023
    GPC3
    |
    GPC3 positive
    |
    GPC3-CAR-T Cells
    Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver Tumors (NCT05123209)
    Phase 1
    Beijing Immunochina Medical Science & Technolog...
    Recruiting
    Last update posted :
    11/17/2021
    Initiation :
    08/24/2021
    Primary completion :
    08/30/2023
    Completion :
    08/30/2023
    PD-L1 • PD-1 • GPC3
    |
    GPC3 expression
    |
    IM83
    Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma (NCT04973098)
    Phase 1
    Peking University
    Recruiting
    Last update posted :
    11/04/2021
    Initiation :
    08/05/2021
    Primary completion :
    08/01/2022
    Completion :
    06/01/2023
    GPC3
    |
    cyclophosphamide • CT0181
    Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors (NCT04951141)
    Phase 1
    Beijing Immunochina Medical Science & Technolog...
    Recruiting
    Last update posted :
    07/05/2021
    Initiation :
    01/01/2019
    Primary completion :
    09/30/2023
    Completion :
    12/21/2023
    GPC3
    |
    GPC3 expression
    |
    IM83
    CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma (NCT03146234)
    Phase N/A
    RenJi Hospital
    Completed
    Last update posted :
    08/28/2019
    Initiation :
    03/17/2017
    Primary completion :
    10/18/2018
    Completion :
    10/18/2018
    GPC3
    |
    GPC3 expression • GPC3 positive
    |
    cyclophosphamide • fludarabine IV • CT0180
    A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART) (NCT03130712)
    Phase 1/2
    Shanghai GeneChem Co., Ltd.
    Unknown status
    Last update posted :
    04/26/2017
    Initiation :
    04/01/2017
    Primary completion :
    03/31/2018
    Completion :
    03/31/2018
    IL6 • IL2RA • GPC3 • IL10
    |
    GPC3 expression
    Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC) (NCT03084380)
    Phase 1/2
    Xinqiao Hospital of Chongqing
    Unknown status
    Last update posted :
    03/20/2017
    Initiation :
    06/01/2017
    Primary completion :
    05/31/2019
    Completion :
    05/31/2020
    GPC3
    |
    GPC3 positive
    |
    cyclophosphamide • fludarabine IV
    Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma (NCT02876978)
    Phase 1
    CARsgen Therapeutics Co., Ltd.
    Unknown status
    Last update posted :
    08/24/2016
    Initiation :
    03/01/2016
    Primary completion :
    10/01/2017
    Completion :
    04/01/2019
    GPC3
    |
    GPC3 positive
    |
    cyclophosphamide • fludarabine IV • CT0180 • cyclophosphamide intravenous
    A Study of GPC3 Redirected Autologous T Cells for Advanced HCC (GPC3-CART) (NCT02715362)
    Phase 1/2
    Shanghai GeneChem Co., Ltd.
    Unknown status
    Last update posted :
    03/22/2016
    Initiation :
    03/01/2016
    Primary completion :
    07/01/2018
    Completion :
    03/01/2019
    IL6 • IL2RA • GPC3 • IL10
    |
    GPC3 expression
    |
    cyclophosphamide • TAI-GPC3-CART cells